Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THIO sequenced with cemiplimab versus single-agent chemotherapy in third-line advanced or metastatic non-small cell lung cancer
2024-520164-33-00Phase 3Authorised
- Sponsor
- MAIA Biotechnology, Inc.
- Start
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, open-label trial of ateganosine and cemiplimab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by MAIA Biotechnology, Inc. Primary endpoint: OS. Planned start Dec 2025; status: authorised.
02
Drugs
ateganosinecemiplimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-520164-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520164-33-00.